Floatz Rating
B63/100
Confidence
Indicative
Sponsor
NeuroDerm Ltd.
Modality
unclassified
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04006210CT.gov Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations | — | Active Not Recruiting | — | — | — |
NCT03462043CT.gov A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension | — | Withdrawn | — | — | — |
NCT02782481CT.gov A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | — | Withdrawn | — | — | — |
NCT02726386CT.gov A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease | — | Active Not Recruiting | — | — | — |
NCT02577523CT.gov A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease | — | Completed | — | — | — |
NCT02604914CT.gov A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects | — | Completed | — | — | — |
NCT01486628CT.gov Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Parkinson Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| nd0612 (this asset) | NeuroDerm Ltd. | P3 | B · 63 |
| Safinamide | Zambon SpA | P4 | A |
| Cvt-301 | Acorda Therapeutics | P3 | A |
| Istradefylline | Georgetown University | P4 | BBB |
| Rasagiline | Guangzhou Henovcom Bioscience Co. Ltd. | P4 | BBB |
| Pardoprunox | Abbott Products | P3 | BBB |
| Opicapone | Bial - Portela C S.A. | P4 | BBB |
| Ropinirole | Titan Pharmaceuticals | P4 | BBB |
| Carbidopa | Tanta University | P4 | BBB |
+42 more in the Parkinson Disease cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. nd0612 in Parkinson Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nd0612-parkinson-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →